The 8:30 panel featuring Yahoo Finance Host Julie Hyman, Senior Autos Reporter Pras Subramanian, and Breaking Business News Reporter Jake Conley examines Novo Nordisk's (NVO ) long-term targets as shares slide amid intensifying competition from Eli Lilly (LLY ). Video Transcript 00:00 Speaker A got to highlight what's going on at Novo Nordisk, which by the way, is now Novo to consumers, but Novo Nordisk to investors and lawyers for that matter. 00:05 Speaker B That's right. 00:06 Speaker A That's right. Um so it's having an investor day today in London and came out with some new plans uh including launching at least five new obesity and diabetes drugs that will be in late stage trials by uh 2030.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.